Comparative Pharmacology
Head-to-head clinical analysis: RENAGEL versus RENVELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENAGEL versus RENVELA.
RENAGEL vs RENVELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sevelamer is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and reducing serum phosphate levels.
Renvela (sevelamer carbonate) is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, inhibiting phosphate absorption and reducing serum phosphate levels. It also binds bile acids, leading to decreased LDL cholesterol.
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 1 tablet/capsule per meal based on serum phosphorus levels. Maintenance: typically 2-4 tablets/capsules per meal.
Adults: 800 mg orally three times daily with meals; titrate based on serum phosphorus levels up to 2400 mg per meal (7200 mg/day maximum).
None Documented
None Documented
Not applicable (non-absorbable polymer; systemic absorption <0.01%).
Not applicable as sevelamer is not absorbed. No systemic half-life; local gastrointestinal transit time is approximately 3-4 hours.
Renal: 0%; Fecal: >99% (as intact drug, due to non-absorbable polymer). Biliary: negligible.
Sevelamer carbonate is not absorbed systemically; excretion is entirely fecal as the parent compound. Less than 0.01% is absorbed and excreted renally.
Category C
Category C
Phosphate Binder
Phosphate Binder